Clinical Trials Browser

Phase 3 × Active not recruiting × Endometrial Neoplasms × Clear all

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT06746116 2026-01-16

DUoENDE

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT06132958 2026-01-09

TroFuse-005

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT05201547 2025-12-04

DOMENICA

Phase 3 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT04634877 2025-06-09

KEYNOTE-B21

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03555422 2025-01-20

ENGOT-EN5

Phase 3 Active not recruiting

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT01820858 2024-04-02

EC-01

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT03469674 2023-10-11

PORTEC-4a

Phase 3 Active not recruiting

Endometrial Neoplasms